SOURCE: IntelliCell BioSciences, Inc.

Intellicell Biosciences, Inc.

October 13, 2015 08:00 ET

Intellicell Biosciences' Flagship Partner, Regen Medical, PC Has Passed QAAAA Office Based Surgery Inspection

NEW YORK, NY--(Marketwired - Oct 13, 2015) - IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company pioneering a new proprietary medical process that results in acquiring Stromal Vascular Fraction Cells (SVFC), announced today that Regen Medical, PC, a New York regenerative medicine company, has passed The American Association for Accreditation of Ambulatory Surgery Facilities' inspection and is fully compliant.

The inspection allows Regen Medical, PC to offer point-of-care cellular therapy to numerous physicians covering a wide variety of specialties. Regen Medical PC will be utilizing Intellicell Biosciences' U.S. Food and Drug Administration (FDA) inspected and registered cellular therapy lab suite and will be purchasing stem cells directly from Intellicell. Regen Medical, PC has two office based surgery rooms with the capacity to perform 50-60 procedures per week. The facility will cater to pain management, orthopedics, aesthetics and neurological conditions.

Dr. Steven Victor, CEO of IntelliCell BioSciences, said, "I am excited that ReGen Medical, PC has been reviewed and has passed its QAAAA inspection, and can now offer physicians the opportunity to perform surgical procedures augmented by Intellicell Cellular Therapy. With Regen Medical, PC as a leading customer, I believe this will create a significant increase in the revenues of Intellicell."

About IntelliCell BioSciences:
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous Stromal Vascular Fraction Cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. This isolation of the cells process is performed in IntelliCell's FDA Registered and Inspected, cGTP cellular lab. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.

About Intellicell BioSciences Cellular Lab Suite:
Intellicell has an FDA registered and Inspected Cellular Therapy Lab Suite which offers our Patented Intellectual Property, best in-class equipment, technical expertise and training, quality assurance and FDA registration and support.

Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact Information

  • CONTACTS:

    Public Relations
    Sean Leous
    Managing Director
    Phone: 1 646 863 8998